The MPD-RC Cores
Core A (Administrative Core)
Core A coordinates activities of the MPD-RC to support all projects and cores, plan and staff committee and board meetings, administer and oversee all budgets and related subcontracts. In addition, Core A maintains communications between members of the MPD-RC, the project sponsor, and external organizations. It assures that National Cancer Institute (NCI) reporting requirements and National Institutes of Health (NIH) regulations are met.
Core B (Biostatistics and Data Management)
Principal Investigator: Judith Goldberg, ScD (New York University)
Co-Principal Investigator: Gianni Tognoni (IRCCS Istituto di Ricerche Farmacologiche Mario Negri)
Core B will provide methodological support to design research activities and perform statistical analysis of information generated from any projects and cores of the MPD-RC. In addition, this core will design, develop, implement and maintain a cutting-edge data collection and management system and facilitate secure access of standardized sets of shared data to investigators within the MPD-RC.
Core C (Tissue Bank)
Principal Investigator: Rona Weinberg (New York Blood Center)
Core C is responsible for tissue banking, sample trafficking and sample validation, including distribution of frozen tissue samples to investigators.
A MPD Tissue Bank is necessary because it will provide the mechanism to collect and distribute tissues from a large number of patients to individual investigators. Because these disorders are relatively rare, individual investigators at a single institution cannot obtain tissues from sufficiently large numbers of patients to reach statistically valid conclusions within a reasonable time frame without Tissue Core C. Tissue Core C will provide tissues from large cohorts of patients at various stages of these disorders, as well as tissues from individual patients collected longitudinally during disease progression. Thus, the Tissue Bank Core C will be an invaluable tool to current and future studies on MPD.The objective is to collect and store tissue samples from patients with myeloproliferative disorders (polycythemia vera [PV], idiopathic myelofibrosis [IM], and essential thrombocythemia [ET]). Tissue samples will be used to conduct laboratory investigation to help define mechanisms involved in the pathophysiology of these disorders. Core C will also perform a variety of laboratory studies, which will be evaluated as biomarkers for the diagnosis and establishment of the prognosis of the Ph- MPD, as well as monitoring responses to particular targeted therapeutic strategies. Posted on September 20 2006 16:56:28